Fundraising Fox

Corvuspharma

Burlingame, US · Founded 2014 · 3 known investors

corvuspharma.com ↗

Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer. Its lead program, soquelitinib, is an oral therapy that selectively inhibits ITK to modulate immune system signaling pathways.

BiotechHealthtech

Founders & leadership

Corvuspharma was founded in 2014 by Richard A. Miller.

RA
Richard A. MillerFounder
LL
Leiv LeaExecutive
TG
Terry G. GouldNamed on SEC filing

Board

E(
Elisha (Terry) P. GouldBoard director
PM
Peter MoldtBoard director
PT
Peter ThompsonBoard director

Investors · 3

Avoro Capital AdvisorsNew York
Foresite CapitalLarkspur
OrbiMedNew York · $1M – $75M

Reported raises · per SEC filings

Form D private placements

$87.7M disclosed across 2 rounds · 2014–2015

▶$75MraisedSep 2015 · 33 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Leiv LeaExecutive Officer
  • Elisha (Terry) P. GouldDirector
  • Peter MoldtDirector
  • Peter ThompsonDirector
  • Richard A. MillerExecutive Officer, Director
Offering amount
$75M
Amount sold
$75M
First sale
Sep 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.7MraisedDec 2014 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard A. MillerExecutive Officer, Director
  • Terry G. GouldDirector
  • Leiv LeaExecutive Officer
  • Peter ThompsonDirector
Offering amount
$33.5M
Amount sold
$12.7M
First sale
Nov 2014
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interestingfinance.yahoo.com · Aug 2026Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Insider Monkeyinsidermonkey.com · Aug 2026Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Simply Wall St Newssimplywall.st · Aug 2026Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com · Aug 2026Earnings call transcript: Corvus posts wider Q2 2026 loss as trials advance By Investing.cominvesting.com · Aug 2026Corvus Pharmaceuticals posts Q2 loss, builds cash | CRVS Quarterly Report (10-Q)stocktitan.net · Aug 2026

Frequently asked questions

What does Corvuspharma do?
Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer. Its lead program, soquelitinib, is an oral therapy that selectively inhibits ITK to modulate immune system signaling pathways.
Who founded Corvuspharma?
Corvuspharma was founded by Richard A. Miller in 2014.
Who are Corvuspharma's investors?
Corvuspharma's investors include Avoro Capital Advisors, Foresite Capital, OrbiMed.
How much funding has Corvuspharma raised?
Corvuspharma has disclosed $87.7M raised across 2 rounds.
Where is Corvuspharma headquartered?
Corvuspharma is headquartered in Burlingame, US.